Ownership and insider activity for ENDRA Life Sciences Inc. (NDRA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood.
Price
| Price | $5.30 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-03-02 | Tokman Alexander Y | A-Award | 26,921 | |
| 2026-03-02 | Jacroux Richard | A-Award | 13,461 | |
| 2026-01-21 | DIGIANDOMENICO ANTHONY | A-Award | 60,324 | |
| 2026-01-21 | Harsh Michael | A-Award | 60,324 | |
| 2026-01-21 | Jacroux Richard | A-Award | 20,000 | |
| 2026-01-21 | Basenese Lou | A-Award | 60,324 | |
| 2026-01-21 | Tokman Alexander Y | A-Award | 75,000 | |
| 2025-10-10 | DIGIANDOMENICO ANTHONY | A-Award | 141,644 | $965K |
| 2025-10-10 | DIGIANDOMENICO ANTHONY | A-Award | 70,822 | $500K |
| 2025-06-11 | Basenese Lou | A-Award | 5,384 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $144953 | $5.6M | $6.5M | $6.2M | $7.2M | $9.5M | $4.9M | $2.8M | $3.2M | $762365 |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | $6850 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | $40105 | $191680 | $59444 | $113442 | $589620 | $1.3M | $2.6M | 0 | 0 | 0 |
| Total Current Assets | $195593 | $5.9M | $6.9M | $6.5M | $8.2M | $12.1M | $8.5M | $3.0M | $3.4M | $967969 |
| Property, Plant & Equipment | $295168 | $241549 | $273233 | $641170 | $551254 | $774543 | $741471 | $465873 | $647294 | $504465 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $490761 | $6.1M | $7.2M | $7.2M | $8.8M | $12.9M | $9.3M | $6.8M | $4.5M | $3.9M |
| Accounts Payable | $227743 | $780261 | $631472 | $1.3M | $402910 | $791052 | $613961 | $360401 | $269683 | $382970 |
| Short-term Debt | $949976 | 0 | 0 | $364262 | $83870 | $117133 | $28484 | $28484 | $169720 | 0 |
| Total Current Liabilities | $1.4M | $848214 | $974583 | $2.1M | $986663 | $1.5M | $1.7M | $903095 | $605230 | $750956 |
| Long-term Debt | 0 | 0 | 0 | 0 | $337084 | $28484 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.4M | $848214 | $974583 | $2.4M | $1.6M | $2.1M | $2.1M | $1.1M | $1.9M | $1.6M |
| Retained Earnings | -$12.5M | -$17.9M | -$27.7M | -$45.2M | -$57.3M | -$68.7M | -$81.9M | -$91.9M | -$103.4M | -$110.5M |
| Total Equity | -$893767 | $5.3M | $6.2M | $4.8M | $7.2M | $10.8M | $7.2M | $5.7M | $2.6M | $2.3M |
| Total Debt | $949976 | 0 | $23 | $773267 | $769342 | $796094 | $546631 | $394403 | $754139 | $492352 |
| Net Debt | $805023 | -$5.6M | -$6.5M | -$5.4M | -$6.5M | -$8.7M | -$4.3M | -$2.4M | -$2.5M | -$270013 |
| Working Capital | -$1.2M | $5.0M | $6.0M | $4.5M | $7.2M | $10.6M | $6.8M | $2.1M | $2.8M | $217013 |
Financial Health
| Debt / Equity | 0.07 |
| Current Ratio | 7.10 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -43.65 |
Profitability
| Return on Equity | -310.93% |
| Return on Invested Capital | -178.30% |
| Return on Assets | -182.35% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BBLG · BGMS · BNBX · DHAI · GCTK · HSCS · ISPC
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of NDRA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks